IXICO (IXI) Stock Overview
Provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IXI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
IXICO plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.075 |
| 52 Week High | UK£0.15 |
| 52 Week Low | UK£0.063 |
| Beta | 0.11 |
| 1 Month Change | 0% |
| 3 Month Change | -13.29% |
| 1 Year Change | -34.78% |
| 3 Year Change | -61.34% |
| 5 Year Change | -90.80% |
| Change since IPO | -87.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| IXI | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | 10.5% | 1.8% |
| 1Y | -34.8% | 1.2% | 17.4% |
Return vs Industry: IXI underperformed the UK Life Sciences industry which returned -4.7% over the past year.
Return vs Market: IXI underperformed the UK Market which returned 16.3% over the past year.
Price Volatility
| IXI volatility | |
|---|---|
| IXI Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: IXI has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: IXI's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 79 | Bram Goorden | ixico.com |
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services.
IXICO plc Fundamentals Summary
| IXI fundamental statistics | |
|---|---|
| Market cap | UK£16.35m |
| Earnings (TTM) | -UK£1.82m |
| Revenue (TTM) | UK£7.28m |
Is IXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IXI income statement (TTM) | |
|---|---|
| Revenue | UK£7.28m |
| Cost of Revenue | UK£3.58m |
| Gross Profit | UK£3.69m |
| Other Expenses | UK£5.51m |
| Earnings | -UK£1.82m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 50.76% |
| Net Profit Margin | -24.98% |
| Debt/Equity Ratio | 0% |
How did IXI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/17 02:38 |
| End of Day Share Price | 2026/09/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IXICO plc is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Christopher Donnellan | Cavendish |
| Hans Bjorn Bostrom | Edison Investment Research |